These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33477145)

  • 1. Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies.
    Gessner C; Potthoff K; Frost N
    Oncol Res Treat; 2021; 44(3):93-102. PubMed ID: 33477145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
    Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
    Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.
    Geßner C; Fietz T; Losem C; Lück A; Schulz H; Niemeier B; Groschek M; Eschenburg H; Weide R; Kretzschmar A; Frost N; Hipp J; Harde J; Matillon CD; Grebhardt S; Potthoff K
    Curr Med Res Opin; 2022 Dec; 38(12):2191-2199. PubMed ID: 36047998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
    Fietz T; Lück A; Schulz H; Harde J; Losem C; Grebhardt S; Wolff T; Potthoff K; Müller U; Zaiss M; Kurbacher CM
    Curr Med Res Opin; 2019 Jul; 35(7):1127-1138. PubMed ID: 30557099
    [No Abstract]   [Full Text] [Related]  

  • 5. NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis.
    Kurbacher CM; Fietz T; Diel IJ; Egert M; Hurtz HJ; Lück A; Weide R; Salat C; Wolff T; Zaiss M; Klare P; Losem C; Illmer T; Weißenborn G; Steffens CC; Schulze M; Tesch H; Oskay-Oezcelik G; Teichmann B; Harde J; Scheuerlein RW
    Oncol Res Treat; 2015; 38(5):221-9. PubMed ID: 25966769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg.
    Fontaine C; Claes N; Graas MP; Samani KK; Vuylsteke P; Vulsteke C
    Acta Clin Belg; 2021 Feb; 76(1):10-15. PubMed ID: 31399016
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
    Volovat C; Bondarenko I; Gladkov O; Buchner A; Lammerich A; Müller U; Bias P
    Support Care Cancer; 2016 Dec; 24(12):4913-4920. PubMed ID: 27501966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting.
    Merseburger AS; Geiges G; Klier J; Wiesholzer M; Pichler P
    Front Oncol; 2021; 11():655355. PubMed ID: 34123810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L; Baser O; Kutikova L; Page JH; Barron R
    Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.
    Holubec L; Polivka J; Lisnerova L; Kubikova T; Safanda M
    In Vivo; 2017; 31(3):303-306. PubMed ID: 28438855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
    Link H; Illerhaus G; Martens UM; Salar A; Depenbusch R; Köhler A; Engelhardt M; Mahlmann S; Zaiss M; Lammerich A; Bias P; Buchner A
    Support Care Cancer; 2021 May; 29(5):2519-2527. PubMed ID: 32944800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
    Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
    BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
    Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
    Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients.
    Timmer-Bonte JNH; Ouwerkerk J; Faber LM; Kerkhofs LGM; Laterveer L; Ten Oever D; van Rees BP; van der Linden PW
    Neth J Med; 2020 Sep; 78(5):270-276. PubMed ID: 33093252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled-analysis of Lipegfilgrastim Effectiveness and Safety Among Patients With Blood Malignancies in the Real-world Setting.
    Pettengell R; Wolff T; Goehler T; Cascavilla N
    Anticancer Res; 2021 Jan; 41(1):347-354. PubMed ID: 33419830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
    Bondarenko IM; Bias P; Buchner A
    Support Care Cancer; 2016 Jan; 24(1):267-273. PubMed ID: 26024743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany.
    Link H; Thompson SF; Tian M; Haas JS; Meise D; Maas C; Dimitrov S
    Support Care Cancer; 2022 Nov; 30(11):9317-9327. PubMed ID: 36076105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.